Research ArticleVaccines

DNA vaccine–derived human IgG produced in transchromosomal bovines protect in lethal models of hantavirus pulmonary syndrome

See allHide authors and affiliations

Science Translational Medicine  26 Nov 2014:
Vol. 6, Issue 264, pp. 264ra162
DOI: 10.1126/scitranslmed.3010082

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Taking Hantavirus by the Horns

Antibodies are the original antiviral. Doctors have leveraged the ability of antibodies to neutralize infection for more than a century, and despite advances in drug development, therapeutic antibodies remain the first-line approach to treat diseases for which no other therapy or vaccine exists. Yet, producing human antibodies remains a challenge. Now, Hooper et al. use DNA vaccine technology in transchromosomal bovines to produce fully human neutralizing antibodies with potent activity against hantavirus, which can lead to a deadly pulmonary syndrome [hantavirus pulmonary syndrome (HPS)] in exposed individuals. Their antibodies protect in lethal animal models of HPS when administered after exposure, supporting further exploration of these next-generation polyclonal immunoglobulin-based medical products.

View Full Text

Stay Connected to Science Translational Medicine